Harmony Biosciences (HRMY) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 86.1% versus a loss of 5.0%. Over five years, HRMY leads with a -13.2% price change compared with -83.2% for MRVI. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.81 billion), about 1.1 times the size.
Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -70.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | MRVI |
|---|---|---|
| Share price | $32.59 | $6.98 |
| Market cap | $1.91B | $1.81B |
| 1-day change | -1.18% | -2.92% |
| YTD return | -12.91% | +114.77% |
| 1-year return | -5.01% | +86.13% |
| 5-year return | -13.21% | -83.18% |
| P/E ratio (TTM) | 10.79 | — |
| Forward P/E | 5.37 | — |
| EPS (TTM) | $3.02 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | $185.74M |
| Revenue growth (YoY) | +21.51% | -28.34% |
| Net income (latest FY) | $158.69M | $-130.77M |
| Gross margin | 77.16% | 18.30% |
| Operating margin | 24.00% | -115.89% |
| Net margin | 18.27% | -70.41% |
| 52-week high | $43.49 | $9.42 |
| 52-week low | $25.90 | $2.80 |
| Distance from 52-week high | -25.06% | -25.90% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +47.53% | +38.11% |
| Average volume | 1.01M | 2.72M |
| Shares outstanding | 58.72M | 149.25M |
| Employees | 293 | 410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed HRMY by 91.1 percentage points over the past year.
- Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -70.4 cents for Maravai LifeSciences.
- Harmony Biosciences grew revenue faster in its latest fiscal year (+21.51% vs -28.34%).
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees
HRMY vs MRVI FAQ
Which is bigger, Harmony Biosciences or Maravai LifeSciences?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.81B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, HRMY or MRVI?
MRVI returned +86.13% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.